Head-to-head evidence
GL0034 vs liraglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
GL0034
Developed by Sun Pharmaceutical Industries
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
liraglutide · Saxenda / Victoza
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GL0034's landscape · liraglutide's landscape